This HTML5 document contains 63 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00797/identifier/national-drug-code-directory/
n7http://linked.opendata.cz/resource/drugbank/company/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00797/identifier/chemspider/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00797/identifier/chebi/
n6http://bio2rdf.org/drugbank:
n12http://linked.opendata.cz/resource/drugbank/drug/DB00797/identifier/wikipedia/
admshttp://www.w3.org/ns/adms#
n15http://linked.opendata.cz/resource/drugbank/drug/DB00797/identifier/pharmgkb/
n19http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00797/identifier/kegg-compound/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n11http://linked.opendata.cz/resource/drugbank/drug/DB00797/identifier/pubchem-compound/
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00797/identifier/pubchem-substance/
xsdhhttp://www.w3.org/2001/XMLSchema#
n21http://linked.opendata.cz/resource/drugbank/drug/DB00797/identifier/drugbank/
n9http://linked.opendata.cz/resource/atc/
n8http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00797
rdf:type
n3:Drug
n3:description
A vasodilator that apparently has direct actions on blood vessels and also increases cardiac output. Tolazoline can interact to some degree with histamine, adrenergic, and cholinergic receptors, but the mechanisms of its therapeutic effects are not clear. It is used in treatment of persistent pulmonary hypertension of the newborn. [PubChem]
n3:group
approved
n3:indication
For the treatment of pulmonary artery anomalies
n3:manufacturer
n7:271B64C2-363D-11E5-9242-09173F13E4C5
owl:sameAs
n6:DB00797 n19:DB00797
dcterms:title
Tolazoline
adms:identifier
n11:5504 n12:Tolazoline n13:46505641 n14:0083-6733-04 n15:PA451716 n17:28502 n18:C07147 n20:5303 n21:DB00797
n3:mechanismOfAction
Vasodilation by means of a direct effect on peripheral vascular smooth muscle and indirect effects produced, in part, by release of endogenous histamine; tolazoline has moderate alpha-adrenergic blocking activity and has histamine agonist activity. Tolazoline usually reduces pulmonary arterial pressure and vascular resistance.
n3:packager
n7:271B64C1-363D-11E5-9242-09173F13E4C5
n3:synonym
2-Benzylimidazoline Tolazolinum Tolazoline 2-Benzyl-2-imidazoline Tolazolina 2-Benzyl-4,5-imidazoline Benzazolin 4,5-Dihydro-2-(phenylmethyl)-1H-imidazole Tolazolin
n3:salt
n3:IUPAC-Name
n4:271B64C7-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B64CD-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B64CC-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B64C9-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B64CA-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B64CB-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B64C5-363D-11E5-9242-09173F13E4C5 n4:271B64DC-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B64C6-363D-11E5-9242-09173F13E4C5 n4:271B64C3-363D-11E5-9242-09173F13E4C5 n4:271B64DE-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B64C4-363D-11E5-9242-09173F13E4C5
n3:pKa
n4:271B64DF-363D-11E5-9242-09173F13E4C5
n8:hasATCCode
n9:M02AX02 n9:C04AB02
n3:H-Bond-Acceptor-Count
n4:271B64D3-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B64D4-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B64CE-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B64CF-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B64D1-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B64D0-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B64D2-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
59-98-3
n3:category
n3:Bioavailability
n4:271B64D8-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B64DA-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B64DB-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B64DD-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B64D7-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B64D6-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B64D9-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B64C8-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B64D5-363D-11E5-9242-09173F13E4C5